16499-54-0

Usage

Uses

Used in Pharmaceutical Industry:
2-Amino-5-trifluoromethylbenzamide is used as a key intermediate in the synthesis of various pharmaceutical compounds for its ability to contribute to the development of new medicinal entities. Its incorporation into drug molecules can enhance their therapeutic efficacy and pharmacological properties, making it an essential component in drug discovery and design.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Amino-5-trifluoromethylbenzamide serves as a crucial building block in the creation of novel agrochemicals. Its unique chemical structure can be leveraged to develop compounds with improved pesticidal activity, selectivity, and reduced environmental impact, thereby contributing to more sustainable agricultural practices.
Used in Research and Development:
2-Amino-5-trifluoromethylbenzamide is utilized as a research tool by chemists and researchers for exploring its anti-inflammatory and analgesic properties. Its potential use in treating various diseases and conditions is under investigation, which could lead to the discovery of new therapeutic agents and contribute to advancements in medical science.
Used in Drug Design and Optimization:
2-AMino-5-trifluoroMethylbenzaMide is employed in the process of drug design and optimization to improve the pharmacokinetic and pharmacodynamic profiles of drug candidates. Its unique chemical features can be exploited to enhance drug absorption, distribution, metabolism, and excretion, as well as to minimize adverse effects, ultimately leading to safer and more effective medications.

Upstream product

• 887144-94-7 Togni's reagent II 
• 28144-70-9 anthranilic acid amide 
• 781-94-2 6-(trifluoromethyl)-2H-benzo[d][1,3]oxazine-2,4(1H)-dione 
• 83265-53-6 2-amino-5-(trifluoromethyl)benzoic acid 
• 1176723-57-1 2-nitro-5-(trifluoromethyl)benzaldehyde 
• 402-14-2 2-nitro-5-(trifluoromethyl)aniline 
• 16499-52-8 2-nitro-5-(trifluoromethyl)benzonitrile 
• 16499-68-6 2-Nitro-5-trifluormethyl-benzamid 

Relevant academic research and scientific papers

Copper-Catalyzed One-Pot Synthesis of Quinazolinones from 2-Nitrobenzaldehydes with Aldehydes: Application toward the Synthesis of Natural Products

A novel, efficient, and atom-economical approach for the construction of quinazolinones from 2-nitrobenzaldehydes has been unveiled via copper-catalyzed nitrile formation, hydrolysis, and reduction in one pot for the first time. In this reaction, urea is used as a source of nitrogen for nitrile formation, hydrazine hydrate is used for both the reduction of the nitro group and the hydrolysis of nitrile, and atmospheric oxygen is used as the sole oxidant. The method portrays a wide substrate scope with good functional group tolerances. Moreover, this method was applied for the synthesis of schizocommunin, tryptanthrin, phaitanthrin-A, phaitanthrin-B, and 8H-quinazolino[4,3-b]quinazolin-8-one.

Synthesis and Nematicidal Activities of 1,2,3-Benzotriazin-4-one Derivatives against Meloidogyne incognita

A series of novel 1,2,3-benzotriazin-4-one derivatives were synthesized by the reaction of 3-bromoalkyl-1,2,3-benzotriazin-4-ones with potassium salt of 2-cyanoimino-4-oxothiazolidine in the presence of potassium iodide. Nematicidal assays in vivo showed that some of them exhibited good control efficacy against the cucumber root-knot nematode disease caused by Meloidogyne incognita, up to 100% at the concentration of 10.0 mg L-1, which indicated that 1,2,3-benzotriazin-4-one derivatives might be potential for novel promising nematicides. The nematicidal activity was influenced by the combination of substituent type, substituted position, and linker length in the molecule. The inhibition rate data at the concentrations of 5.0 and 1.0 mg L-1 for the compounds with high inhibitory activities were also provided. When tested in vitro, none of them showed direct inhibition against M. incognita. The investigation of a significant difference between in vivo and in vitro data is in progress.

SUBSTITUTED 2- AMIDOQUINAZOL-4-ONES AS MATRIX METALLOPROTEINASE-13 INHIBITORS

The present invention provides a novel amide derivative having a matrix metalloproteinase inhibitory activity, and useful as a pharmaceutical agent, which is a compound represented by the formula (I) wherein ring A is an optionally substituted, nitrogen containing heterocycle, ring B is an optionally substituted monocyclic homocycle or an optionally substituted monocyclic heterocycle, Z is N or NR1 (R1 is a hydrogen atom or an optionally substituted hydrocarbon group), is a single bond or a double bond, R2 is a hydrogen atom or an optionally substituted hydrocarbon group, X is an optionally substituted spacer having 1 to 6 atoms, ring C is (1) an optionally substituted homocycle or (2) an optionally substituted heterocycle other than a ring represented by (II) (X′ is S, O, SO, or CH2), and at least one of ring B and ring C has substituent(s), provided that N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]2 hydroxypropyl}5,6 dimethyl 4 oxo 1,4 dihydrothieno[2,3-d]pyrimidine-2-carboxamide is excluded, or a salt thereof.

Visible-light-promoted radical C-H trifluoromethylation of free anilines

The trifluoromethyl-substituted anilines are biologically active compounds and useful building blocks. In this communication, we have developed the first visible-light-induced radical trifluoromethylation of free anilines with the commercially available and easily handled Togni reagent at room temperature. The resulting products were successfully transformed into a variety of valuable fluorine-containing molecules and heterocyclic compounds. This protocol provides an economical and powerful route to trifluoromethylated free anilines.